Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03190837 · ClinicalTrials.gov registry record
A Long-term Follow-up Study of Gaucher Disease
A clinical trial of Gaucher Disease, sponsored by Duke University.
- Recruiting
- Registry status
- 200
- Enrollment target
- 1
- Study location
NCT03190837: Recruiting study of Gaucher Disease, sponsored by Duke University.
NCT03190837 is a study of Gaucher Disease that is actively recruiting participants, run by Duke University. The registered enrollment target is 200 participants, below the 1,043-participant average among 13 other Gaucher Disease trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03190837, a study of Gaucher Disease, is actively recruiting participants, sponsored by Duke University.
- RECRUITING
- Registry status
- 200 participants
- Enrollment target
- 1
- Study location
Study Summary
The study aims are to: a) identify the long-term natural history of Gaucher disease, b) evaluate long-term treatment efficacy of enzyme replacement therapy (ERT) and substrate reduction therapy (SRT), and c) identify potential long-term complications of this disorder. These aims will be accomplished through long-term record review of individuals with all three types of Gaucher disease.
Primary Outcome
Use Gaucher patient's natural histories to understand effects of Gaucher Disease long term.
Conditions Studied
Study Locations (1)
North Carolina
- Duke University Medical Center - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2017-06-12 |
| Est. Completion | 2027-01 |
What NCT03190837 shows while recruiting
NCT03190837 is an observational study that tracks outcomes without assigning an intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 1,043-participant average among 13 other Gaucher Disease trials with a reported enrollment target (81% lower).
The record links to 1 condition, with Gaucher Disease appearing as the primary indexed condition, and to 0 interventions.
NCT03190837 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT03190837 about?
NCT03190837 is a clinical study titled "A Long-term Follow-up Study of Gaucher Disease". The study aims are to: a) identify the long-term natural history of Gaucher disease, b) evaluate long-term treatment efficacy of enzyme replacement therapy (ERT) and substrate reduction therapy (SRT), and c) identify potential long-term complications of this disorder. These aims will be accomplished...
What is the current status of trial NCT03190837?
This trial is currently recruiting. The enrollment target is 200 participants. The study started on 2017-06-12. Estimated completion is 2027-01.
What conditions does trial NCT03190837 study?
This clinical trial studies the following conditions: Gaucher Disease.
Who is sponsoring clinical trial NCT03190837?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03190837 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gaucher Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03190837's enrollment target sits among peer trials
200 3rd of 13 higher than 11 of 13 other Gaucher Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Gaucher Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Extracellular Vesicles as Potential Biomarkers and Therapeutic Target in Gaucher Disease
RECRUITING
-
Gaucher Disease Outcome Survey (GOS)
RECRUITING
-
International Collaborative Gaucher Group (ICGG) Gaucher Disease Registry & Pregnancy Sub-registry
RECRUITING
-
The GBA Multimodal Study in Parkinson's Disease
RECRUITING
-
Drug Discovery for Parkinson's With Mutations in the GBA Gene
RECRUITING
-
A Clinical Trial of PR001 (LY3884961) in Patients With Peripheral Manifestations of Gaucher Disease (PROCEED)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI